OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer ...
Company Intends to Enter Clinic with OSE-172 in Oncology by End of 2018 Data presented at 15th Annual “Discovery on Target” Conference NANTES, France, Oct. 02, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) presented new …